Diagast

What Diagast does

Diagast is a French in vitro diagnostic (IVD) medical device company founded in 1988 and headquartered in Loos, France, specializing exclusively in immunohematology — the science of blood grouping and pre-transfusion compatibility testing. The company designs, manufactures, and commercializes a complete portfolio of reagents, instruments, and consumables for blood banks, hospital transfusion centers, and clinical laboratories. Its proprietary technology stack centers on E.M. Technology (Erythrocyte Magnetization), which combines magnetization of red blood cells with solid-phase indirect antiglobulin testing, and M-TRAP Technology for manual techniques. The flagship automated platform is the QWALYS 3 EVO, a fully automated immunohematology analyzer used for blood grouping, phenotyping, and irregular antibody screening, complemented by the ABD PAD rapid blood group confirmation device (results in under 30 seconds without sample preparation), ABTest Card for bedside pre-transfusion verification, and a broad reagent range covering Anti-A/B/AB/D, phenotyping systems (RH, Kell, Duffy, Kidd, MNS), and I-Mag Screen antibody screening panels.

Diagast generates revenue through multiple streams: direct hardware and reagent sales in France, export sales managed from headquarters, an extensive distributor network spanning nearly 100 countries, regional subsidiaries in Spain (DIAGAST Ibérica) and India, OEM bulk reagent supply to other diagnostic manufacturers, and professional training services delivered at the DIAGAST Training Center. Pricing is quote-based with no public price list. The company has achieved several regulatory milestones, including IVDR Regulation 2017/746 Quality Management System certification in 2022, first CE markings in March 2023, and notably the first IVDR Class D certification (the highest risk category) for its Anti sera PK reagents targeting Beckman Coulter PK7300 and PK7400 analyzers.

The company employs between 101 and 250 people and remains privately held with no recorded external funding rounds. Its customer base is fragmented across thousands of blood banks and clinical laboratories globally, served primarily through distributors, with select strategic relationships including the French Blood Service (EFS) via U.C.I.L. for external quality assessment programs and Servicios Quirúrgicos S.A. for Central American distribution. The 2014 acquisition of ABO DIAG consolidated the company's immunohematology footprint.

Name

Diagast

Legal name

DIAGAST

Website

https://diagast.com

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Immunohematology Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)

akta.pro secondary industries

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM), Hematology & Coagulation Diagnostics (HLAHAAAB), Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG), Quality Control, Calibrators, Standards & Proficiency Testing (IVD Consumables) (HLAHAAAL)

Keywords

• Immunohematology diagnostics
• Blood grouping reagents
• Transfusion medicine devices
• Blood bank automation
• Pre-transfusion safety

Headquarters

HQ city

Loos

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Diagnostic Medical Devices and Reagents: Sale of in vitro diagnostic medical devices including automated reagents, manual test reagents, blood grouping reagents, and phenotyping reagents for immunohematology applications in blood banks and transfusion centers.
2. Automated Instruments: Sale and service of automated analyzers including QWALYS 3 EVO and PK7300/PK7400 compatible reagents.
3. Training Services: Training programs for product specialists, field service engineers, operators, and end users conducted at DIAGAST Training Center or customer premises.
4. OEM Products: Bulk reagent products (concentrated and ready-to-use) sold to other manufacturers for integration into their own offerings.
5. Quality Control Products: Internal and external quality control products for laboratory accreditation compliance (ISO 15189, French L.6221-9 requirements).

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Diagast designs, manufactures, and sells in vitro diagnostic reagents and instrumentation for immunohematology, covering blood group determination, antibody screening/identification, and pre-transfusion safety testing. Its portfolio combines automated analyzer systems (e.g., QWALYS 3 EVO) with single-use consumables such as test cards (ABTest Card, ABD PAD), microplates (MANUAL PLATE), and reagent kits sold to blood banks, hospital transfusion services, and clinical laboratories.

Product overview

DIAGAST is a French in vitro diagnostics company specializing in immuno-hematology since 1988. The product portfolio centers on the QWALYS 3 EVO automated immuno-hematology platform utilizing proprietary E.M. Technology, complemented by manual testing solutions including the ABD PAD rapid blood group confirmation device and MANUAL PLATE consumables. Transfusion safety is addressed through ABTest Card and Safety Card products. The comprehensive reagent portfolio includes blood grouping reagents (Anti-A, Anti-B, Anti-D, Anti-AB, Anti-A1), phenotyping reagents (RH, Kell, Duffy, Kidd, MNS systems), and irregular antibody screening products (I-Mag Screen, ScreenLys). Quality assurance is supported through internal quality controls (HEMA CQI, SERA CQI, ABS IQC) and external quality assessment programs in partnership with U.C.I.L./EFS. OEM bulk reagents and training services round out the offerings for laboratory partners worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• QWALYS 3 EVO
• ABD PAD
• ABTest Card
• MANUAL PLATE
• Diagast Reagents Portfolio (red blood cell reagents, anti-sera, antibody screening/identification panels, M-TRAP platelet antibody reagents)

Quantifiable outcome

• Blood group confirmation in under 30 seconds without sample preparation
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Servicios Quirúrgicos S.A.coreChannel Partner/ Reseller/ DistributorCommercial distributor for the Guatemalan market. DIAGAST partnered with Servicios Quirúrgicos to introduce QWALYS 3 EVO, E.M. Technology, and ABD PAD to blood banks in Guatemala. Servicios Quirúrgicos has strong presence in cardiology, oncology, neurology, and diabetes, expanding into immunohematology with DIAGAST's portfolio.
• U.C.I.L. (Établissement Français du Sang)coreStrategic or Co-development PartnerPartnership with the Interlaboratory Control Unit of the French Blood Service to offer external quality assessment (EQA) programs for blood grouping, phenotyping, and antibody testing. UCIL prepares 4 campaigns annually per French law L.6221-9 and ISO 15189 requirements.
• Hydrex Diagnostics Sp. z o.o.minorOEM/ Whitelabel/ Licensing PartnerManufacturer of MANUAL PLATE products for DIAGAST. Located in Warsaw, Poland (Aleja Stanów Zjednoczonych 61a, 04-028 Warszawa).

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Bio-Rad Laboratories: Bio-Rad's Clinical Diagnostics division is one of the largest global suppliers of immunohematology reagents, blood-typing instruments, and quality controls, directly competing with Diagast's QWALYS-based offering and reagent portfolio across blood banks and transfusion centers.
• Grifols: Grifols, through its Immucor acquisition, is a leading provider of transfusion and transplantation diagnostics, including automated blood-typing analyzers and reagents. It competes head-to-head with Diagast in immunohematology labs worldwide.
• Quotient Limited: Quotient's MosaiQ transfusion diagnostics platform competes with Diagast's QWALYS 3 EVO in the automated immunohematology segment, targeting blood banks and transfusion centers with molecular and serological testing.
• Ortho Clinical Diagnostics: Ortho Clinical Diagnostics is a major global provider of immunohematology products (including the ORTHO VISION and ORTHO Workstation platforms), directly competing with Diagast in hospital blood-bank automation and reagents.

Broad incumbents

• Beckman Coulter Diagnostics: Beckman Coulter's PK7300 and PK7400 automated blood-grouping systems use Diagast-supplied antisera reagents under OEM, and Beckman competes more broadly in hematology / IVD. It is a strategic OEM customer and adjacent competitor in immunohematology automation.
• Siemens Healthineers: Siemens Healthineers offers comprehensive IVD and blood-bank solutions through its laboratory diagnostics portfolio, competing for the same hospital and lab budgets as Diagast, although immunohematology is not its primary focus.
• Roche Diagnostics: Roche Diagnostics is a global IVD leader with central-lab platforms; while immunohematology is a smaller focus, Roche competes for integrated lab tenders that include blood-bank testing alongside chemistry and immunoassay.
• Abbott Diagnostics: Abbott provides broad IVD and hematology instrumentation; although its core is not transfusion medicine, it competes for hospital diagnostic budgets that include blood-bank procurement.

Emerging players

• Bühlmann Laboratories: Bühlmann Laboratories is a Swiss specialty diagnostics company with focused products in immunology and blood-bank diagnostics. Its narrower product scope and European base make it a partial-overlap competitor to Diagast's specialty portfolio.

Others

• Meso Scale Diagnostics: Meso Scale Diagnostics operates in specialty IVD and life-science tools adjacent to immunohematology reagents. It is thematically related through bioproduction and reagent manufacturing scale rather than direct competition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/user/DIAGAST
• Facebookfacebook.com/DIAGAST-259509102178
• LinkedInlinkedin.com/company/diagast
• Instagraminstagram.com/diagast

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diagast